Beth Valashinas, DO
Rheumatology · Orange, CTNPI 1114184306
Payments from drug & device makers
Across 744 payments — averaging $108.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$51K
- GSK$16K
- Progentec Diagnostics, Inc.$2K
- UCB, Inc.$2K
- Amgen$2K
- Bristol Myers Squibb$1K
- plus $6K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 217 | $50,850 |
| GSK | 64 | $15,709 |
| Progentec Diagnostics, Inc. | 1 | $2,400 |
| UCB, Inc. | 45 | $2,267 |
| Amgen(2 entities) | 120 | $2,150 |
| Bristol Myers Squibb | 6 | $1,475 |
| E.r. Squibb & Sons, L.L.C. | 71 | $1,394 |
| Johnson & Johnson | 55 | $1,300 |
| Pfizer | 46 | $817 |
| Novartis | 21 | $437 |
| Lilly USA, LLC | 20 | $434 |
| Sanofi | 19 | $405 |
| Genentech USA, Inc. | 12 | $241 |
| AstraZeneca(2 entities) | 8 | $208 |
| Boehringer Ingelheim | 9 | $189 |
| Aurinia Pharma U.S., Inc. | 6 | $118 |
| ANI Pharmaceuticals, Inc. | 4 | $114 |
| Mallinckrodt Hospital Products Inc. | 4 | $113 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $59 |
| Fresenius Kabi USA, LLC | 2 | $48 |
| Radius Health, Inc. | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Invivyd Inc | 1 | $35 |
| Medexus Pharma, Inc. | 2 | $30 |
| Mallinckrodt Enterprises LLC | 1 | $23 |
| Merck | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Sandoz | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $19 |
How this compares
$80,986 in reported general payments places this provider in the 85th percentile of 118 rheumatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Orange
- Fotios KoumpourasNorth Haven$1.5M
- Kenneth MillerDanbury$930K
- Monique HinchcliffNorth Haven$883K
- Robert SchoenGuilford$638K
- Stuart NovackNorwalk$507K
- Bret SohnStamford$460K
- Geoffrey GladsteinTrumbull$452K
- John MagaldiTorrington$451K
- Joseph CraftNew Haven$357K
- Richard RoseffDanbury$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.